Cysteine Protease inhibitor hydrochloride
Based on 3 publication(s) in Google Scholar
Cysteine Protease inhibitor hydrochloride, an inhibitor of Cysteine Protease, binds to acetylcholinesterase (AChE). Cysteine Protease inhibitor hydrochloride is applicable to the research of Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity: 96.01%
- CAS No.: 2197053-49-7
- Formula: C18H15ClN4O
- Molecular Weight:338.79
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-103352
L-006235
-
HY-100231
Cathepsin inhibitor 1
-
HY-146985
Cathepsin X-IN-1
-
HY-114374
RO5461111
-
HY-D0843
N-Ethylmaleimide
-
HY-B0496
PMSF
-
HY-148905
p-Aminophenylmercuric acetate
-
HY-100350
CA-074 methyl ester
-
HY-15533
LY 3000328
-
HY-10042
Odanacatib
-
HY-103351
Cathepsin G Inhibitor I
-
HY-15100
Balicatib
Publications Citing Use of MedChemExpress (MCE) Cysteine Protease inhibitor hydrochloride
MoreAll Cathepsin Isoforms
More
Biological Activity
Chemical Information
-
CAS No. 2197053-49-7
-
Appearance Solid
-
Molecular Weight 338.79
-
Formula C18H15ClN4O
-
Color White to off-white
-
SMILES
N#CC1=NC(OC2=CC(C3=CC=C(CN)C=C3)=CC=C2)=CC=N1.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Nerve Growth Factor Signaling Promotes Nuclear Translocation of TRAF4 to Enhance Tumor Stemness and Metastatic Dormancy Via C-Jun-mediated IL-8 Autocrine. [Abstract]2025 Feb;12(7):e2414437. PMID: 39716976 -
Cell Chem Biol
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. [Abstract]2021 Jun 17;28(6):855-865.e9. PMID: 33979649 -
Sci Rep
Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. [Abstract]2022 Jul 16;12(1):12197. PMID: 35842458
Solvent & Solubility
DMSO : 50 mg/mL (147.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9517 mL | 14.7584 mL | 29.5168 mL | 73.7920 mL |
| 5 mM | 0.5903 mL | 2.9517 mL | 5.9034 mL | 14.7584 mL | |
| 10 mM | 0.2952 mL | 1.4758 mL | 2.9517 mL | 7.3792 mL | |
| 15 mM | 0.1968 mL | 0.9839 mL | 1.9678 mL | 4.9195 mL | |
| 20 mM | 0.1476 mL | 0.7379 mL | 1.4758 mL | 3.6896 mL | |
| 25 mM | 0.1181 mL | 0.5903 mL | 1.1807 mL | 2.9517 mL | |
| 30 mM | 0.0984 mL | 0.4919 mL | 0.9839 mL | 2.4597 mL | |
| 40 mM | 0.0738 mL | 0.3690 mL | 0.7379 mL | 1.8448 mL | |
| 50 mM | 0.0590 mL | 0.2952 mL | 0.5903 mL | 1.4758 mL | |
| 60 mM | 0.0492 mL | 0.2460 mL | 0.4919 mL | 1.2299 mL | |
| 80 mM | 0.0369 mL | 0.1845 mL | 0.3690 mL | 0.9224 mL | |
| 100 mM | 0.0295 mL | 0.1476 mL | 0.2952 mL | 0.7379 mL |
Cysteine Protease inhibitor hydrochloride Related Classifications
HY-17541A Related Classifications
Powered by Bioz